A Phase II, Open-label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease

Trial Profile

A Phase II, Open-label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Autologous cultured kidney tissue cells (Primary)
  • Indications Kidney disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors RegenMed
  • Most Recent Events

    • 07 Aug 2017 Status changed from recruiting to completed.
    • 14 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 05 Apr 2016 Planned initiation date changed from 1 Aug 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top